Eisai Co., Ltd. (4523.T) JPX

3,818.00

+10(+0.26%)

Updated at June 02 03:30PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Haruo Naito	Chief Executive Officer, Representative Corporate Officer & Director	190M	1947
Yanhui Feng	Senior Vice President	191M	1972
Gary Hendler	Senior Vice President & President of EMEA Region	198M	1966
Lynn D. Kramer FAAN	Vice President & Chief Clinical Officer	305M	1950
Teruyuki Masaka	Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs	0	1978
Akiko Nakahama	Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology	0	1968
Makoto Hoketsu	Vice President & Chief Information Officer	0	1970
Takuya Oyama	Vice President, Chief Financial Officer & Chief IR Officer	0	N/A
Keisuke Naito	Representative Corporate Officer, EVP, COO & Chief Growth Officer	0	1988
Shin Kato	Vice President, General Counsel & Chief Compliance Officer	0	1971
Katsutoshi Ido	Vice President, Chief Scientific Officer & Head of DHBL Discoverry	0	N/A

Name

Title

Pay

Year Born

Haruo Naito

Chief Executive Officer, Representative Corporate Officer & Director

190M

1947

Yanhui Feng

Senior Vice President

191M

1972

Gary Hendler

Senior Vice President & President of EMEA Region

198M

1966

Lynn D. Kramer FAAN

Vice President & Chief Clinical Officer

305M

1950

Teruyuki Masaka

Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs

1978

Akiko Nakahama

Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology

1968

Makoto Hoketsu

Vice President & Chief Information Officer

1970

Takuya Oyama

Vice President, Chief Financial Officer & Chief IR Officer

N/A

Keisuke Naito

Representative Corporate Officer, EVP, COO & Chief Growth Officer

1988

Shin Kato

Vice President, General Counsel & Chief Compliance Officer

1971

Katsutoshi Ido

Vice President, Chief Scientific Officer & Head of DHBL Discoverry

N/A

Description

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.